These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

743 related articles for article (PubMed ID: 27660695)

  • 41. Metformin: Is it Still the First Line in Type 2 Diabetes Management Algorithm?
    Grammatiki M; Sagar R; Ajjan RA
    Curr Pharm Des; 2021; 27(8):1061-1067. PubMed ID: 33355048
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Pharmacologic treatment of type 2 diabetes: injectable medications.
    Tran L; Zielinski A; Roach AH; Jende JA; Householder AM; Cole EE; Atway SA; Amornyard M; Accursi ML; Shieh SW; Thompson EE
    Ann Pharmacother; 2015 Jun; 49(6):700-14. PubMed ID: 25802244
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Alpha-glucosidase inhibitors for prevention or delay of type 2 diabetes mellitus and its associated complications in people at increased risk of developing type 2 diabetes mellitus.
    Moelands SV; Lucassen PL; Akkermans RP; De Grauw WJ; Van de Laar FA
    Cochrane Database Syst Rev; 2018 Dec; 12(12):CD005061. PubMed ID: 30592787
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Oral Glucose-lowering Drugs and Cardiovascular Outcomes: From the Negative RECORD and ACCORD to Neutral TECOS and Promising EMPA-REG.
    Tsioufis C; Andrikou E; Thomopoulos C; Papanas N; Tousoulis D
    Curr Vasc Pharmacol; 2017; 15(5):457-468. PubMed ID: 27928947
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Efficacy and Safety of Basal Insulin-Based Treatment Versus Twice-Daily Premixed Insulin After Short-Term Intensive Insulin Therapy in Patients with Type 2 Diabetes Mellitus in China: Study Protocol for a Randomized Controlled Trial (BEYOND V).
    Liu J; Jiang X; Xu B; Wang G; Cui N; Zhang X; Liu J; Mu Y; Guo L
    Adv Ther; 2020 Apr; 37(4):1675-1687. PubMed ID: 32130661
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Advancing therapy in type 2 diabetes mellitus with early, comprehensive progression from oral agents to insulin therapy.
    Vinik A
    Clin Ther; 2007; 29 Spec No():1236-53. PubMed ID: 18046925
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Outcomes and treatment patterns of adding a third agent to 2 OADs in patients with type 2 diabetes.
    Levin PA; Wei W; Zhou S; Xie L; Baser O
    J Manag Care Spec Pharm; 2014 May; 20(5):501-12. PubMed ID: 24761822
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Glucagon-Like Peptide-1 Receptor Agonist Use in People Living with Type 2 Diabetes Mellitus and Chronic Kidney Disease: A Narrative Review of the Key Evidence with Practical Considerations.
    Górriz JL; Romera I; Cobo A; O'Brien PD; Merino-Torres JF
    Diabetes Ther; 2022 Mar; 13(3):389-421. PubMed ID: 35175551
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Budget Impact of Oral Semaglutide Intensification versus Sitagliptin among US Patients with Type 2 Diabetes Mellitus Uncontrolled with Metformin.
    Wehler E; Lautsch D; Kowal S; Davies G; Briggs A; Li Q; Rajpathak S; Alsumali A
    Pharmacoeconomics; 2021 Mar; 39(3):317-330. PubMed ID: 33150566
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Head-to-head comparison of intensive lifestyle intervention (U-TURN) versus conventional multifactorial care in patients with type 2 diabetes: protocol and rationale for an assessor-blinded, parallel group and randomised trial.
    Ried-Larsen M; Christensen R; Hansen KB; Johansen MY; Pedersen M; Zacho M; Hansen LS; Kofoed K; Thomsen K; Jensen MS; Nielsen RO; MacDonald C; Langberg H; Vaag AA; Pedersen BK; Karstoft K
    BMJ Open; 2015 Dec; 5(12):e009764. PubMed ID: 26656025
    [TBL] [Abstract][Full Text] [Related]  

  • 51. EMPA-REG and Other Cardiovascular Outcome Trials of Glucose-lowering Agents: Implications for Future Treatment Strategies in Type 2 Diabetes Mellitus.
    Schernthaner G; Schernthaner-Reiter MH; Schernthaner GH
    Clin Ther; 2016 Jun; 38(6):1288-1298. PubMed ID: 27210264
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Pioglitazone for prevention or delay of type 2 diabetes mellitus and its associated complications in people at risk for the development of type 2 diabetes mellitus.
    Ipsen EØ; Madsen KS; Chi Y; Pedersen-Bjergaard U; Richter B; Metzendorf MI; Hemmingsen B
    Cochrane Database Syst Rev; 2020 Nov; 11(11):CD013516. PubMed ID: 33210751
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Insights from VERIFY: Early Combination Therapy Provides Better Glycaemic Durability Than a Stepwise Approach in Newly Diagnosed Type 2 Diabetes.
    Matthews D; Del Prato S; Mohan V; Mathieu C; Vencio S; Chan JCN; Stumvoll M; Paldánius PM
    Diabetes Ther; 2020 Nov; 11(11):2465-2476. PubMed ID: 32975711
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Type 2 diabetes mellitus--current therapies and the emergence of surgical options.
    Lebovitz HE
    Nat Rev Endocrinol; 2011 Feb; 7(7):408-19. PubMed ID: 21301486
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Pharmacologic treatment of type 2 diabetes: oral medications.
    Tran L; Zielinski A; Roach AH; Jende JA; Householder AM; Cole EE; Atway SA; Amornyard M; Accursi ML; Shieh SW; Thompson EE
    Ann Pharmacother; 2015 May; 49(5):540-56. PubMed ID: 25667196
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Review of models used in economic analyses of new oral treatments for type 2 diabetes mellitus.
    Asche CV; Hippler SE; Eurich DT
    Pharmacoeconomics; 2014 Jan; 32(1):15-27. PubMed ID: 24357160
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Pharmacologic management of the older patient with type 2 diabetes mellitus.
    Neumiller JJ; Setter SM
    Am J Geriatr Pharmacother; 2009 Dec; 7(6):324-42. PubMed ID: 20129254
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Noninsulin treatment of type 2 diabetes mellitus in geriatric patients: a review.
    Germino FW
    Clin Ther; 2011 Dec; 33(12):1868-82. PubMed ID: 22136979
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Insulin in type 2 diabetes: a useful alternative despite limited assessment based on surrogate endpoints.
    Prescrire Int; 2005 Oct; 14(79):187-93. PubMed ID: 16285076
    [TBL] [Abstract][Full Text] [Related]  

  • 60.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 38.